Arrowhead Pharmaceuticals (ARWR) Replaces $400M Loan at SOFR Plus 5.50%

Arrowhead Pharmaceuticals reported that plozasiran reduced acute pancreatitis events by 78% overall and 91% in patients with recent history. ARO-DIMER-PA showed LDL-C and triglyceride reductions. Results were not placebo-adjusted. The data supports Arrowhead's cardiometabolic pipeline.

Arrowhead's plozasiran reduced acute pancreatitis events by 91% in severe hypertriglyceridemia patients with recent attacks. ARO-DIMER-PA showed LDL-C reductions up to 65% and triglyceride reductions up to 78%. Data presented at AHA Scientific Sessions 2026.

Arrowhead Pharmaceuticals refinanced its debt with Sixth Street, lowering borrowing costs to SOFR plus 5.50% from 15%, reducing the prepayment amount by $68 million, and extending maturity to 2031. The new facility improves liquidity and operational flexibility, according to the company. Sixth Street cited Arrowhead's progress as a reason for continued support.

Arrowhead Pharmaceuticals refinanced its debt with a $400 million loan from Sixth Street Lending Partners, due in 2031. The company used the new loan and cash to repay prior loans totaling $404.4 million, removing high-interest debt and improving financial flexibility.

Arrowhead Pharmaceuticals (ARWR) will present clinical data at the American Heart Association Scientific Sessions 2026. Key presentations include results from a Phase 1/2a study of ARO-DIMER-PA for mixed hyperlipidemia, a pooled analysis of plozasiran in severe hypertriglyceridemia (sHTG), and long-term data on plozasiran in familial chylomicronemia syndrome (FCS). Plozasiran is under review for sHTG and approved for FCS in several regions.

Arrowhead Pharmaceuticals received UK marketing approval for Redemplo (plozasiran) to treat familial chylomicronaemia syndrome (FCS). NICE recommended NHS funding for eligible patients. The approval is based on Phase III trial results showing efficacy in reducing triglyceride levels. Arrowhead aims to expand availability in Europe.